Black Diamond Therapeutics, Inc.

Ownership Transactions Reported by 21 Insiders

Symbol
BDTX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
One Main Street, 14 Th Floor, Cambridge, MA

Insiders trading volume in the past year

Black Diamond Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Versant Venture Capital VI, L.P. 10%+ Owner $28.7M -$1.4M -4.65% Aug 28, 2024
Biotech Growth N V 10%+ Owner $23.3M Oct 17, 2023
Ali Behbahani Director $11.3M Dec 13, 2024
Ra Capital Management, L.P. Director $8.77M Jul 5, 2023
David M. Epstein Officer Title: President and Chief Executive Officer, Director $1.88M Jun 27, 2023
Wendy L. Dixon Director $173K Mar 15, 2024
Mark A. Velleca PRESIDENT & CEO, Director $127K Feb 14, 2024
Robert Alexander Ingram Former Director $117K Dec 16, 2022
Erika Jones Officer Title: Vice President, Finance and Corporate Controller $27.7K Feb 14, 2024
Prakash Raman Director $25.4K Dec 13, 2024
Shannon Campbell Director $22.2K Dec 13, 2024
Brent Hatzis-Schoch Officer Title: Chief Operating Officer and General Counsel Feb 14, 2024
Kapil Dhingra Director Jun 6, 2024
Rajeev M. Shah Director May 16, 2023
Samarth Kulkarni Director Jun 6, 2024
Sergey Yurasov Chief Medical Officer Feb 14, 2024
Alexander Mayweg Director May 16, 2023
Elizabeth Buck Chief Scientific Officer Feb 14, 2024
Fang Ni Officer Title: Chief Business Officer and Chief Financial Officer Feb 14, 2024
E. Garry Menzel Director Jun 6, 2024
Bradley J. Bolzon PhD Director, 10%+ Owner Jun 18, 2021

Recent Insider Transactions by Companies or Individuals for Black Diamond Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.